Abstract:3106 Background: NTRK gene fusion resulting from NTRK1/2/3 genetic alterations occurs in various adult and pediatric cancers, which is one of the most defined driving factors of carcinogenesis. Patients with NTRK fusion positive cancers treated by earlier generation TRK inhibitors achieve rapid and durable responses but can develop on-target resistance. ICP-723 is a highly selective next-generation TRK inhibitor. In preclinical studies, ICP-723 not only markedly inhibits the activity of the wild type TRKA/B/C, but also shows robust activity against resistant mutations, e.g., G595R, F589L or G667C/A/S. A first-in-human clinical study is currently ongoing to evaluate the safety, tolerability, pharmacokinetics (PK) characteristics and efficacy of ICP-723. Methods: This is a multi-center, open-label phase I/II clinical trial, which includes a phase I dose escalation part and a phase II dose expansion part. In the phase I dose escalation, patients with advanced solid tumor, who failed from clinical standard of care or for whom there is currently no effective therapy, will be enrolled. The modified "3+3" method is followed for dose escalation. Results: As of 11Feb2022, a total of 17 patients in phase I dose escalation were treated with ICP-723 at doses of 1 mg QD to 8 mg QD. The median age of the enrolled patients was 54 yrs, (range: 31 to 69 yrs) and ECOG performance status was between 0-1 (58.8% had ECOG PS of 1). Six of 17 patients were confirmed as NTRK gene fusion positive tumors by either prior gene test reports or the central lab gene test. There is no DLT observed in the 6 dose groups. Most AEs were manageable and grade 1-2. The most common TRAEs (> 20%) were asthenia (23.5%), increased ALT (29.7%), increased AST (29.7%) and anemia (29.7%). Gr ≥3 TRAEs were increased ALT (5.9%), increased AST (5.9%), increased CPK (11.8%), neutrophil count decreased (5.9%) and pain (5.9%). The plasma exposure to ICP-723 increased in a dose proportional manner across the observed dosage levels. According to RECIST 1.1 criteria, among the 6 patients with NTRK fusion, the overall response rate (ORR) was 66.7% (4 patients with partial response (PR)), the disease control rate (DCR) was 100%. It is worth noting that one patient with measurable brain metastasis achieved PR with the target brain lesion shrunk from 10 mm to 3 mm. All patients who achieved PR responded to ICP-723 at the first tumor assessment after 4-week treatment and maintained sustained responses to the date of data cutoff. Conclusions: ICP-723 is safe and well-tolerated in patients with advanced solid tumors. Encouraging clinical efficacy including intracranial activity was demonstrated in patients with NTRK gene fusion in various tumor types. Enrollment in phase I is ongoing until the final RP2D is determined, then phase II expansion will be conducted in patients with defined gene alterations. Clinical trial information: NCT04685226.

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers

Roles of tropomyosin-related kinases in tumorigenesis and their small molecular inhibitors

Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review

Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions

Tropomyosin Receptor Kinase B (trkb) Signalling: Targeted Therapy in Neurogenic Tumours

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance

Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation

Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs

Pyrazolo[1,5- a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors-Synthetic Strategies and SAR Insights

Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults

NTRK Therapy among Different Types of Cancers, Review and Future Perspectives

Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor

NTRK fusions in lung cancer: From biology to therapy

Design of novel anti-cancer drugs targeting TRKs inhibitors based 3D QSAR, molecular docking and molecular dynamics simulation

The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma.

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6 H-pyrimido[5,4- b][1,4]oxazin-7(8 H)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants

Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene

Safety, Pharmacokinetics (PK), and Clinical Efficacy of ICP-723, a Highly Selective Next-Generation Pan-Trk Inhibitor, in Patients with Solid Tumor.

NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications